Literature DB >> 33341160

Reconceptualising treatment-resistant depression as difficult-to-treat depression.

R Hamish McAllister-Williams1, Celso Arango2, Pierre Blier3, Koen Demyttenaere4, Peter Falkai5, Philip Gorwood6, Malcolm Hopwood7, Afzal Javed8, Siegfried Kasper9, Gurjhinder S Malhi10, Jair C Soares11, Eduard Vieta12, Allan H Young13, Andreas Papadopoulos14, Augustus J Rush15.   

Abstract

Entities:  

Mesh:

Year:  2021        PMID: 33341160     DOI: 10.1016/S2215-0366(20)30516-2

Source DB:  PubMed          Journal:  Lancet Psychiatry        ISSN: 2215-0366            Impact factor:   27.083


× No keyword cloud information.
  5 in total

1.  The burden associated with, and management of, difficult-to-treat depression in patients under specialist psychiatric care in the United Kingdom.

Authors:  Tiago Costa; Bayar Menzat; Tomas Engelthaler; Benjamin Fell; Tarso Franarin; Gloria Roque; Yiran Wei; Xinyue Zhang; R Hamish McAllister-Williams
Journal:  J Psychopharmacol       Date:  2022-05-04       Impact factor: 4.562

2.  Mortality-causing mechanisms and healthcare resource utilisation of treatment-resistant depression: A six-year population-based cohort study.

Authors:  Vivien Ky Chan; Edmund Cl Cheung; Sandra Sm Chan; Martin Knapp; Joseph F Hayes; Min Fan; Francisco Tt Lai; Hao Luo; Terry Lum; Rosa Sm Wong; Lauren Kw Lau; Eric Yf Wan; Gloria Hy Wong; Esther Wy Chan; Patrick Ip; Ian Ck Wong; Xue Li
Journal:  Lancet Reg Health West Pac       Date:  2022-03-15

Review 3.  Anti-TNF-α Compounds as a Treatment for Depression.

Authors:  Sarit Uzzan; Abed N Azab
Journal:  Molecules       Date:  2021-04-19       Impact factor: 4.411

4.  Normobaric oxygen treatment for mild-to-moderate depression: a randomized, double-blind, proof-of-concept trial.

Authors:  Yehudit Bloch; R H Belmaker; Pesach Shvartzman; Pnina Romem; Arkady Bolotin; Yuly Bersudsky; Abed N Azab
Journal:  Sci Rep       Date:  2021-09-23       Impact factor: 4.379

Review 5.  A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials.

Authors:  Luca Sforzini; Courtney Worrell; Melisa Kose; Ian M Anderson; Bruno Aouizerate; Volker Arolt; Michael Bauer; Bernhard T Baune; Pierre Blier; Anthony J Cleare; Philip J Cowen; Timothy G Dinan; Andrea Fagiolini; I Nicol Ferrier; Ulrich Hegerl; Andrew D Krystal; Marion Leboyer; R Hamish McAllister-Williams; Roger S McIntyre; Andreas Meyer-Lindenberg; Andrew H Miller; Charles B Nemeroff; Claus Normann; David Nutt; Stefano Pallanti; Luca Pani; Brenda W J H Penninx; Alan F Schatzberg; Richard C Shelton; Lakshmi N Yatham; Allan H Young; Roland Zahn; Georgios Aislaitner; Florence Butlen-Ducuing; Christine Fletcher; Marion Haberkamp; Thomas Laughren; Fanni-Laura Mäntylä; Koen Schruers; Andrew Thomson; Gara Arteaga-Henríquez; Francesco Benedetti; Lucinda Cash-Gibson; Woo Ri Chae; Heidi De Smedt; Stefan M Gold; Witte J G Hoogendijk; Valeria Jordán Mondragón; Eduard Maron; Jadwiga Martynowicz; Elisa Melloni; Christian Otte; Gabriela Perez-Fuentes; Sara Poletti; Mark E Schmidt; Edwin van de Ketterij; Katherine Woo; Yanina Flossbach; J Antoni Ramos-Quiroga; Adam J Savitz; Carmine M Pariante
Journal:  Mol Psychiatry       Date:  2021-12-15       Impact factor: 13.437

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.